Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: REDX
Market: AIM
52-week High/Low: 67.80p / 23.00p
Sector: Pharma & Biotech
Market Cap: 40.95M
Phone: +44 (0)151 706 4747
Address: Royal Liverpool Univeristy Hospital, Daulby Street, Liverpool L69 3GA.
Website: RedxPharma.com
Redx Pharma Plc

Redx Pharma Plc

Redx Pharma is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high unmet medical need, in cancer, immunology and infection. By improving the characteristics of existing drug classes, we aim to create differentiated, novel drugs.

Redx has an established portfolio of proprietary drug programs that it is developing alone and in partnership with leading pharmaceutical companies and healthcare bodies. Two of our high value programs are advancing into Phase I clinical development for gastric, biliary and pancreatic cancers, and leukaemia. It is our aim that our discoveries will provide a pipeline of potential assets to complement and combine with the drug portfolios of larger and emerging pharmaceutical companies.

Redx Pharma Plc

RedxPharma.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Redx Pharma Plc


Redx Pharma Plc Snapshot

Redx Pharma (formed in September 2010) has three subsidiaries: Redx Oncology Ltd launched in April 2012, Redx Anti-Infectives Ltd launched in April 2013 and Redx Immunology Ltd launched in May 2015.

 

Redx Anti-Infectives 

Redx Anti-Infectives Ltd is a wholly-owned subsidiary of Redx Pharma, a UK-based company discovering and developing new therapeutics for the global pharmaceutical market.

Redx has successfully applied its proprietary Redox Switch™ approach in the area of infectious disease generating a pipeline of novel antibacterial and antiviral drugs.

The recent calls from the World Health Organisation and the UK's Chief Medical Officer for greater efforts to be invested in the discovery of new antibiotics have highlighted the chronic lack of new therapies in this area. Redx Anti-Infectives, in collaboration with its partners, is playing its part in tackling this issue with a key focus on developing drugs to combat antibiotic resistance.

Application

Antibacterials

Although sales of anti-infective drugs represent around 11% of the global pharmaceutical market, every year 25,000 people in the EU die as a result of a serious drug resistant infection – mostly acquired in healthcare settings. The WHO has launched a major initiative to urge governments and the pharmaceutical industry to promote new R&D efforts to develop new anti-infective medicines.

There is a chronic need for new and novel antibacterial agents, particularly to address those increasingly prevalent organisms with inherent natural resistance to current antimicrobials (eg Acinetobacter baumannii) and those acquiring new resistance mechanisms (eg E. Coli and Klebsiella spp.). Redx Anti-Infectives is applying the company's proprietary Redox Switch™ platform to tackle this critical medical need.

Redx has rapidly generated a pipeline of programs that seek to address drug resistance. We are pursuing both broad and narrow spectrum approaches against Gram-positive and Gram-negative organisms.

Antivirals

Drug resistance to current small molecule influenza therapies is a growing problem that seriously threatens our ability to cope with future pandemic flu outbreaks.

By employing its novel Redox Switch™ chemistry approach, Redx Anti-Infectives is generating new candidate drugs with activity against both resistant and wild-type influenza strains.

Application

Antibacterials

Although sales of anti-infective drugs represent around 11% of the global pharmaceutical market, every year 25,000 people in the EU die as a result of a serious drug resistant infection – mostly acquired in healthcare settings. The WHO has launched a major initiative to urge governments and the pharmaceutical industry to promote new R&D efforts to develop new anti-infective medicines.

There is a chronic need for new and novel antibacterial agents, particularly to address those increasingly prevalent organisms with inherent natural resistance to current antimicrobials (eg Acinetobacter baumannii) and those acquiring new resistance mechanisms (eg E. Coli and Klebsiella spp.). Redx Anti-Infectives is applying the company's proprietary Redox Switch™ platform to tackle this critical medical need.

Redx has rapidly generated a pipeline of programs that seek to address drug resistance. We are pursuing both broad and narrow spectrum approaches against Gram-positive and Gram-negative organisms.

Antivirals

Drug resistance to current small molecule influenza therapies is a growing problem that seriously threatens our ability to cope with future pandemic flu outbreaks.

By employing its novel Redox Switch™ chemistry approach, Redx Anti-Infectives is generating new candidate drugs with activity against both resistant and wild-type influenza strains.

Redx Oncology

Redx Oncology was the first subsidiary formed by parent company Redx Pharma in April 2012. With over 190 people Redx Pharma is now one of the largest R&D pharmaceutical biotech employers in the UK and over 80 of these staff work within Redx Oncology. The company currently has a broad portfolio of novel oncology programs including three nominated development candidates (Btk, SMO, porcupine).

Redx Oncology works on small molecule approaches to cancer medicines with a focus on targeted medicines which will address key areas of unmet need such as pancreatic cancer, as well as developing second generation medicines which will treat emerging resistance to current therapies. The company also has a portfolio of immune-oncology programs which look to harness the immune system to fight the cancer. This is an area of cancer research which is showing great promise and is expected to become a key aspect of cancer therapy approaches in the future. The early results with launched antibodies such as the anti-PD-1 (Keytruda, Opdivo) and anti-CTLA-4 (Yervoy) have created a stir in the cancer research field but much remains to be done in terms of improving response rates so that this approach can benefit a wider patient population. Redx Oncology is working to develop small molecule drugs for use in combination with these antibodies to enhance their efficacy and increase the number of people who respond to treatment.

Redx Immunology

Redx Pharma announced the launch of its third subsidiary, Redx Immunology, in May 2015. The company will focus on developing new therapies for disorders of the immune system.

It is intended that Redx Immunology will deliver up to eight new drug development candidates over the near to medium term for subsequent progression into clinical trials. The launch of Redx Immunology is in line with the Group's stated strategy to develop a third therapeutic area to generate additional pipeline assets for further partnering and licencing deals. Its creation also complements Redx's current cancer-related drug programs which encompass immuno-oncology.

Redx Immunology's approach to drug discovery and development will be consistent with the Company's existing approach in its cancer and anti-infectives subsidiaries. It will focus on commercially relevant targets and seek to improve the characteristics of existing drug classes to create highly differentiated best-in-class new drugs. As with its other subsidiaries, Redx will seek partnership and licence deals at an early stage in drug development programs.

Mr Iain Ross (Non-Executive Chairman) joined the Company on 1 May 2017. Iain currently serves as Non-Executive Chairman of AIM quoted e-Therapeutics plc and Biomer Technology Ltd alongside his Non-Executive Directorships at London listed Premier Veterinary Group plc, ASX quoted Anatara LifeSciences Ltd and Novogen Ltd, and as a Director of Aldershot Town Football Club.
Iain’s previous executive positions include Executive Chairman at Silence Therapeutics plc (2005-2010), Chief Executive Officer at Allergy Therapeutics (2001-2002), Chief Executive Officer at Quadrant Healthcare plc (1995-2000) and Main Board Director of Celltech Group plc and CEO of Celltech Biologics (1991-1995). He has also been a Non-Executive Director at Benitec Biopharma (2010-2016), Phadia AB (2004-2007) and Eden BioDesign (2003-2007). Prior to this he worked at several multinational companies including Sandoz AG, Fisons plc and Hoffman La Roche. Mr Ross is a qualified Chartered Director (UK IoD) and Vice Chairman of Royal Holloway, London University.

 

Dr Neil Murray (CEO) co-founded the Company in 2010 and has over 25 years’ experience in the pharmaceutical industry with experience of drug development, business growth and general management. He has held a variety of senior operational, commercial and R&D positions including as Global Director for Sales and Marketing with Solutia's Pharmaceutical Services business. Prior to joining Solutia he was Director of Chemical Development at Vernalis (formerly Vanguard Medica) with additional responsibility for management of the company's research portfolio. He was also European Business Development Director for SigmaAldrich before which he was External Projects Director at GlaxoWellcome with responsibility for the company's external development science. He has extensive experience of drug discovery and development and commercialisation in large and small companies across a wide range of therapeutic areas.

 

Mr Norman Molyneux (Non-Executive Director) was previously the CFO of the Company before becoming a Non-Executive Director in September 2014. Norman is a qualified Chartered Management Accountant and has 15 years’ experience in arranging early stage business angel and venture capital funding. Following training in accountancy with GKN, he joined PriceWaterhouseCoopers, working on many consultancy assignments with both SME and multinational companies. Following this, he returned to industry with director roles in the paper manufacturing and food manufacturing sectors in the UK. In 2000, Norman founded Acceleris Limited, an FCA regulated fund management and corporate finance firm specialising in EIS-led investment transactions. Norman holds numerous directorships fulfilling both executive and non-executive positions.

 

Dr Bernhard Kirschbaum (Non-Executive Director) joined the Board in January 2016. Bernhard has over 25 years' experience in pharmaceutical research and drug development, having held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel. He has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. In the eight years to 2013, he worked at Merck/Merck Serono, becoming a member of the Board and Executive Vice-President, Global Research & Early Development. He was responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company's R&D portfolio, with over 70 programs, doubling the number of phase II assets in this period. Dr Kirschbaum is currently a board member of BioMedX, Protagen Diagnostics, and OMEICOS Therapeutics.

 

David Lawrence (Non-Executive Director) joined the Board in May 2016. David has over 25 years' experience in the biotech and pharmaceutical industries with a strong track record in strategy, business development and commercial management, including working with a number of investors, biotech start-ups and SMEs. He is currently a Non-Executive Director at Synpromics Ltd, a synthetic biology company that he co-founded. In 2014-2015 he was CEO of Sentintext Therapeutics, a biotech focussed on the development of vaccines for enterviruses. He was also a director of QSpine Limited, which designs, manufactures and distributes surgical spine medical devices. David has been Chairman of Ambicare Health Limited, CEO of Tayside Flow Technologies Ltd and formerly worked at Chiron Vaccines (now part of Novartis), Acambis plc (now part of Sanofi), and GlaxoSmithKline.

Management

Dr Neil Murray (CEO), as above

 

Dr Richard Armer (CSO) joined Redx in 2012, becoming Chief Scientific Officer in 2014. He has significant experience in both small biotechnology and large pharmaceutical companies through his roles within Pfizer, Organon, Ardana, Oxagen, Lectus Therapeutics. Richard's expertise is in drug discovery with a particular focus on lead optimisation activities, drug disposition, intellectual property and commercial scientific project positioning. He has experience across a wide range of therapeutic areas and has been successful in generating and progressing multiple clinical candidates.

 

Nicholas Adams (CBO) joined as the Company's first Chief Business Officer at the end of 2015. Nick has over 25 years' experience in the pharmaceutical industry, and in particular in business development. He has led a wide range of deal types, including in- and out-licensing, divestments, royalty buy-outs as well as M&A. He has also worked in clinical development in large and mid-sized pharmaceutical companies and in biotech. Most recently, he was Chief Business Officer of Clavis Pharma ASA, the Norwegian drug development company specialising in oncology. Prior to that, he was Vice President of Business Development at Antisoma Research plc, which developed therapies for cancer and autoimmune disease.

 

Dr Matilda Bingham (Head of Research & Operations) has 14 years’ experience in drug discovery and joined the company in 2012. Matilda’s scientific background is in medicinal chemistry having worked at Organon, Schering-Plough and Merck (MSD) before joining the management team at Redx Pharma. Matilda played a key role in setting up the Redx Oncology subsidiary including laboratory design, recruitment, development of health and safety policies and the creation of the current project portfolio. In 2015 she was promoted from Head of Chemistry to Executive Director and currently manages the Oncology and Immunology subsidiaries.

 

Dr Karl Hård (Head of Investor Relations and Corporate Communications) has spent almost 20 years at AstraZeneca, the last nine of which included senior roles within Investor Relations, latterly as Vice President. Before that, he worked as Global Programme Director, establishing new external collaborations, and as Director in Biological Chemistry, leading research into novel pharmacological targets. His scientific experience covers oncology, immunology and infection.

Karl was Assistant Professor in Chemistry at Leiden University, The Netherlands, and holds a PhD in Chemistry from Utrecht University, and an MSc in Biochemistry from Helsinki University, Finland.

 

Andrew Booth (Interim Finance Director) holds a degree in Law from Liverpool University, and is a qualified member of the Institute of Chartered Accountants in England & Wales. His areas of expertise include listed company work and International Financial Reporting Standards. Andrew started his career with PKF (now BDO LLP), before moving to work in industry, taking on a number of senior financial roles in AIM and Euronext listed companies (including that of Company Secretary). He joined Redx Pharma as Group Financial Controller in July 2015 and became Interim Finance Director in September 2016.

Shareholders with >3% of total issued:

Name Number of shares Percentage of
issued shares
Seneca Partners 15,792,781 12.49%
Moulton Goodies Ltd 13,643,107 10.79%
Axa Investment Managers 12,417,336 9.82%
Lanstead Capital LP 12,075,000 9.55%
Aviva Plc 10,644,816 8.42%
Graham Edwards 3,999,900 3.16%

Last updated 18/04/17

Redx Pharma logo

Block 33
Mereside
Alderley Park
Macclesfield
SK10 4TG

01625 469 900

 

Business Development

Nicholas Adams
Block 33
Mereside
Alderley Park
Macclesfield
SK10 4TG

01625 238 972

 

Investor Relations

Karl Hård
Block 33
Mereside
Alderley Park
Macclesfield
SK10 4TG

+44 7491 651 406

 

Human Resources

Redx Pharma HR
PO Box 707
Wakefield
WF1 9PJ

01924 566 080

 

Financial PR

Consilium Strategic Communications
41 Lothbury
London
EC2R 7HG

020 3709 5700

 

Public Relations

Chris Hulme
Influential
5th Floor, Oxford Place
61 Oxford Street
Manchester
M1 6EQ

0161 804 1400

Nominated Adviser & Broker
Cantor Fitzgerald Europe
One Churchill Place
London E14 5RB, UK

Joint Broker
WG Partners LLP
85 Gresham Street
London EC2V 7NQ, UK

Corporate Finance Adviser
Acceleris Capital Ltd
Lowry House
17 Marble Street
Manchester M2 3AW, UK

Auditor
RSM UK Audit LLP
3 Hardman Street
Manchester M3 3HF, UK

Legal Advisers
Covington and Burling LLP
265 Strand
London WC2R 1BH, UK

DWF LLP
1 Scott Place
2 Hardman Street
Manchester M3 3AA, UK

Registrar
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex BN99 6DA, UK

 

Redx Pharma Plc Timeline

CN Research
April 06 2017

Columns Including REDX

VIEW ALL

Market Reports Including REDX

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use